Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Document › Details

Optimapharm d.d.. (7/21/20). "Press Release: Optimapharm Appoints Dr. Andrew Copestake as Chief Executive Officer".

Organisations Organisation Optimapharm d.d.
  Group Optimapharm (Group)
  Organisation 2 TRG Management L.P. (The Rohatyn Group)
  Group TRG Management (The Rohatyn Group) (Group)
Products Product clinical research services
  Product 2 private equity
  Index term 2 Optimapharm–TRG Management: investment, 202005 investment by The Rohatyn Group to grow organically + via acquisitions
Persons Person Copestake, Andrew (Optimapharm 202007– CEO)
  Person 2 Greguric Cicak, Gordana (Otpimapharm 202007– COO before CEO + Founder since 2006)
     


Optimapharm is pleased to announce that Dr. Andrew Copestake has been appointed Chief Executive Officer, effective 20 th July 2020. Andrew joins Optimapharm’s executive management team following several months advising the company’s Board of Directors.

Andrew brings almost 30 years industry experience, having worked in large multinational pharmaceutical companies, global and regional contract research organizations, the biotech sector, as well as other service providers. He also brings a global approach, having gained international experience during appointments in the USA, Japan and throughout Europe. Andrew holds a PhD in Respiratory & Exercise Physiology from Loughborough University, UK and a Bachelor Degree (Hons) in Applied Biology from East London University, UK. He is also a Fellow of the Royal Society of Medicine.

Andrew’s appointment comes at an important inflexion point for Optimapharm. Following The Rohatyn Group’s investment in Optimapharm, announced in May 2020, Optimapharm is rapidly expanding the scale and breadth of its services to continue to build on its reputation for delivery excellence and a client-focused approach throughout Europe. Andrew will add a layer of seasoned leadership and experience running global full-service companies and is immediately focused on further developing Optimapharm’s service offering to capitalise on the current market opportunity in Europe.

In his new role, Andrew will work very closely with Dr. Gordana Greguric Cicak, Optimapharm’s founder, who will continue to lead Optimapharm’s operations as Chief Operating Officer. Gordana will maintain day-to-day responsibility for Optimapharm’s Clinical Operations, Clinical Project Management and Regulatory & Safety teams, ensuring industry-leading project delivery, quality outcomes whilst consistently exceeding client expectations.

With Andrew and Gordana at the helm, Optimapharm is uniquely placed to expand its customer base and operational capabilities, in-line with our vision to accelerate our development into the first-choice European CRO.

   
Record changed: 2020-08-06

Advertisement

Picture [iito] No Tracking 650x80px

More documents for Optimapharm (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px




» top